Curing Cancer Part 1

October 21st 2025

Cancer is one of humanity’s oldest and most persistent enemies. For centuries, it’s defied our best attempts to control it - mutating, hiding, and evolving faster than our treatments could keep up. Yet today, we’re closer than ever to changing that story. This deep dive, split into two parts, explores both the science and business of the modern fight against cancer.

Part 1 explains the full arc of progress: why cancer is so difficult to cure, how scientists have learned to outsmart it, and the breakthroughs, from prevention and early detection to precision drugs and immune-based therapies, that have already saved millions of lives. It also looks ahead at the hardest problems still to solve, from treatment resistance to dormant “sleeper” cells, and the technologies now being developed to defeat them.

Part 2 shifts perspective, examining the organizations driving the next wave of innovation in oncology - from AI-powered drug discovery and genomic testing to radiopharmaceuticals and precision manufacturing. It explores how this rapidly evolving ecosystem is reshaping one of the world’s largest and most influential industries: the business of fighting cancer.

Together, these two parts show how the world’s longest medical battle is entering a new phase - one defined not by a single cure but by a growing network of breakthroughs and businesses transforming how cancer is detected, treated, and ultimately overcome. Readers will come away with a clearer picture of where science is heading, the technologies moving fastest, and the innovators building a future where cancer becomes not an inevitability, but a challenge we can manage and eventually defeat.

If you’re new to this newsletter, you can join free here to get more deep dives on the innovations shaping our world.

Why Curing Cancer Is So Difficult

If cancer were a single disease, we might already have cured it. But it isn’t. It’s thousands of different illnesses that all share one defining trait: cells that break the rules.

To make sense of it, imagine the human body as a vast, living city. Every citizen (cell) has a job to do - building, repairing, communicating - and follows the city’s laws written in our DNA. Cancer begins when a few of those “citizens” stop following the rules. They start ignoring signals to stop multiplying and recruit others to join them. Soon, they form a criminal network that spreads through the city, dodging police patrols (the immune system) and hijacking resources meant for everyone else.

That’s why “curing cancer” isn’t one challenge; it’s more like trying to track down thousands of different gangs operating in the same city, each with its own methods and hiding places.

A city of many gangs: One of the biggest reasons cancer is so hard to cure is that no two cancers are truly alike. Even when two people have the same type of cancer - say, breast or lung - their tumors can be driven by completely different genetic mutations. And inside a single tumor, not all cells are the same. Some divide quickly, others lie low. Some are resistant to one drug, others to another. Scientists call this heterogeneity, and it’s one of cancer’s most frustrating traits.

In our city metaphor, that’s like discovering that every gang on a single street has a different playbook. You can take down one group, but a slightly different one pops up next door, immune to the same tactics. Treatments that wipe out one part of a tumor often leave behind small pockets of cells that survive and rebuild. It’s like mowing the lawn - the blades disappear, but the roots remain.

The spread - when gangs move across the city: Even when doctors eliminate the main tumor, cancer has a way of spreading to new territory, a process called metastasis. Stray cancer cells can travel through the bloodstream or lymph system, landing in new “neighborhoods” such as the liver, lungs, brain, or bones. Once there, they adapt again - changing shape and behavior to fit their new surroundings.

That’s what makes metastasis so dangerous. It’s like a criminal network opening safe houses in new districts. The local environment - the blood–brain barrier, oxygen levels, the immune defenses - can all differ dramatically, so the old strategy doesn’t work anymore. Some cells even go into hiding, lying dormant for years before re-emerging to rebuild. These dormant cells are one of the main reasons cancer can return long after a patient seems cured.

The neighborhood problem: A tumor doesn’t exist in isolation. Around it is a whole microenvironment - a mix of blood vessels, immune cells, connective tissue, and chemical signals. This neighborhood often ends up working in the tumor’s favor. It can block drugs from entering, suppress immune attacks, and even feed the tumor’s growth.

It’s as if the gangs start bribing local officials and recruiting residents. The once-peaceful neighborhood becomes a safe zone for criminal activity. Scientists call this the tumor microenvironment (TME), and it’s one of the hardest parts of cancer to crack. Unless we change the neighborhood itself, even the best drugs can struggle to get through.

Disguises and decoys: The immune system should, in theory, be our best defense against cancer. It constantly patrols the body, looking for abnormal cells to destroy. But cancer has evolved tricks to hide from it. Some tumors stop displaying the “identity badges” that immune cells look for. Others flip special molecular switches called checkpoints that tell immune cells to stand down.

It’s like gang members wearing stolen police uniforms. The real police can’t tell friend from foe. Until recently, this was one of the biggest reasons cancer could grow unchecked even in people with healthy immune systems.

The arms race: Even when we do hit cancer hard - with chemotherapy, radiation, or new targeted drugs - it fights back. Cancer cells mutate constantly, and the ones that survive treatment pass their resistance traits on to future generations. It’s evolution in fast-forward.

If you imagine the body as a city at war with its own insurgents, each drug is a new tactic. Sometimes it works brilliantly for a while, shrinking tumors or stopping their growth. But the remaining cells learn from the attack. They rewrite their code, switch off vulnerable pathways, or activate stress responses that help them survive. One of these survival systems is autophagy, a process where cells recycle their own material to survive tough conditions - like looters scavenging supplies to outlast a siege.

This constant back-and-forth - attack, adapt, attack again - is why cancer treatment so often becomes a marathon rather than a single decisive strike.

The limits of early detection: Finding cancer early gives us the best chance of stopping it, but even that’s complicated. Many cancers grow silently for years before causing symptoms. By the time they’re visible on scans or felt as lumps, they’ve often spread. The problem is detection tools must strike a delicate balance: make them too sensitive, and they risk false positives; make them too cautious, and they miss real cases. It’s like listening for a single suspicious radio signal in a city full of noise.

The bigger picture: When you put it all together, cancer isn’t one villain - it’s an evolving network of rule-breakers that hide, adapt, and infiltrate. To cure it, we need to identify every disguise, disrupt every hiding place, and stay one step ahead as it changes its playbook. It’s a lifelong chase - but one that science is finally beginning to turn in our favor.

The Progress Made So Far

For all its cunning, cancer is losing ground. Step by step, scientists, doctors, and patients have reduced its threat - not through one miracle cure, but through countless coordinated advances. Over the last 30 years, the world has seen the sharpest sustained drop in cancer deaths in history. Since 1991, mortality rates have fallen by more than a third, sparing around 4.5 million lives in the United States alone. Each percentage point represents people who lived to see another birthday, another decade, another generation.

Fewer new cases, more lives saved: One of the biggest victories has come not from treatment but from prevention. Decades of anti-smoking campaigns have prevented millions of lung cancer deaths. Globally, smoking rates have halved since their peak, and with them, lung cancer deaths have fallen dramatically. In the U.S. alone, falling tobacco use accounts for roughly half of the overall decline in cancer mortality. It’s proof that the simplest weapon, stopping the cause, can be the most powerful.

Prevention now goes far beyond tobacco. Two vaccines - one against HPV, another against hepatitis B - are already stopping cancers before they begin. The HPV vaccine, given to teenagers in many countries, has nearly eliminated cervical cancer among young women in the U.K. and Scotland. In those who received it as early teens, new cases are now close to zero. Meanwhile, hepatitis B vaccination has drastically reduced liver cancer rates across Asia and parts of Africa, and antiviral treatments are helping protect adults already infected. In Japan and Taiwan, treating or eradicating Helicobacter pylori, a stomach bacterium linked to ulcers, has led to steep drops in stomach cancer.

Catching cancer earlier: For those cancers that can’t be fully prevented, early detection has been a lifesaver. Regular screening for breast, colorectal, cervical, and prostate cancers has caught disease at earlier, more treatable stages - often long before symptoms appear.

The humble stool test for bowel cancer, for instance, has quietly become one of medicine’s most effective tools. In major population studies, those who complete the test have about a third lower risk of dying from the disease. Colonoscopies and improved surgical techniques then remove precancerous growths before they can turn deadly.

Mammograms, when combined with more precise surgery and drug therapy, have driven breast-cancer death rates down steadily year after year. Today, more than eight in ten women diagnosed in developed countries survive at least five years, and many live far longer. Cervical-cancer screening, now increasingly automated and AI-assisted, continues to save hundreds of thousands of lives every year.

Together, these screening programs mean that cancers once discovered too late are now being found early enough to cure. The result: fewer emergencies, more quiet victories.

Smarter, more targeted treatments: When prevention and early detection aren’t enough, treatment has become vastly more precise. The old approach was like carpet-bombing - high doses of chemotherapy that attacked everything, good and bad. The new strategy is targeted, data-driven, and increasingly personal.

Take chronic myeloid leukemia (CML). In the 1990s, it was almost always fatal within a few years. Then came imatinib, the first targeted drug to block the specific enzyme driving the disease. For many patients, it turned a death sentence into a chronic, manageable condition. Today, people with CML often live normal lifespans, taking a daily pill instead of enduring years of harsh chemotherapy.

The same revolution reached breast cancer in the early 2000s with trastuzumab, better known as Herceptin, which targets a protein called HER2 that fuels tumor growth in about one in five patients. Adding it to treatment cut recurrence rates dramatically and improved survival, and newer generations of antibody-based drugs have built on that success, extending benefits to even more women.

And then there’s testicular cancer, once one of the most lethal diseases in young men. Combination chemotherapy built around cisplatin pushed cure rates from about 10% in the 1970s to over 90% today, one of the most complete turnarounds in all of medicine.

Each of these breakthroughs taught the same lesson: when you understand a tumor’s inner wiring, you can shut down its power source instead of blowing up the whole city block.

Harnessing the immune system: For decades, the immune system was the sleeping giant of cancer care. Doctors knew it could fight infections - but not that it could fight cancer too. That changed with the arrival of checkpoint inhibitors, drugs that remove the “do not attack” signs cancer cells use to hide.

The results were extraordinary. In melanoma, once a near-certain killer in its advanced stages, patients now routinely live years longer; some are functionally cured. Similar drugs have improved survival in lung, kidney, and head and neck cancers, with combinations proving even more effective. These therapies don’t work for everyone, but when they do, the results can last - sometimes indefinitely.

For the first time, medicine learned not just how to poison cancer, but how to train the body to fight it itself.

Better, faster, kinder radiotherapy: Even radiation, one of the oldest cancer tools, has evolved into a high-precision craft. Modern radiotherapy uses advanced imaging and AI-guided planning to target tumors with millimeter accuracy. Treatments that once took six weeks can now take one, with equal or better results. Fewer visits, fewer side effects, and faster recovery times are the new norm. It’s the same principle as replacing air raids with guided drones: less collateral damage, more direct hits.

A generation growing up after cancer: Perhaps the most heartening progress is among children. In the 1960s, a diagnosis of acute lymphoblastic leukemia (ALL) was almost always fatal. Today, more than 90% of children survive it, and many go on to live full adult lives. Across the board, childhood-cancer survival has climbed steadily thanks to better chemotherapy regimens, improved infection control, and more personalized risk assessment.

Even for adults, survivorship has changed. In high-income countries, two in three people diagnosed with cancer today will live at least five years - up from one in two in the 1990s. Millions now live decades beyond diagnosis, returning to work, raising families, and often helping others through the same journey.

The Key Problems That Remain - and How We’re Tackling Them

Despite the huge progress of recent decades, cancer remains one of medicine’s most adaptable foes. Each time we close in, it finds a new way to survive - mutating, hiding, or turning our own biology to its advantage. The next breakthroughs will come not from one miracle cure, but from a deeper understanding of how this disease evolves and how we can stay one step ahead.

Outsmarting cancer’s ability to adapt: The first big challenge is resistance. Every time a treatment works, some cancer cells find a way around it. They change their genetic code, activate backup pathways, or switch off the targets our drugs are built to hit.

To fight back, scientists are shifting strategy. Instead of relying on a single powerful drug, they’re using combination treatments that block multiple escape routes at once, or sequenced therapies that change tactics mid-way through treatment before cancer can adapt. The field of synthetic lethality, hitting two linked genes at once so that when one is blocked the other becomes fatally vulnerable, is beginning to reshape drug development. And new trial designs are testing combinations dynamically rather than one at a time.

AI is accelerating this process in remarkable ways. Machine-learning models now sift through millions of molecular interactions to predict which combinations will work best together - a task that would take human researchers years. By simulating cancer evolution in silico, AI can even predict how tumors might resist future drugs, allowing scientists to stay one move ahead.

Breaking through cancer’s defensive walls: The next challenge lies in the tumor microenvironment - the neighborhood around the tumor that often works against us. Dense scar-like tissue, chaotic blood vessels, and immune-suppressing cells create a fortress that keeps drugs and immune cells out.

New therapies aim to re-landscape this hostile terrain. Some drugs normalize blood flow so medicines can reach their targets; others dismantle the fibrous scaffolding that blocks entry. Researchers are also developing nanoparticles that can slip through these barriers and deliver drugs directly into tumors, and drugs that trigger immunogenic cell death - a kind of controlled demolition that draws the immune system into the fight.

AI is helping here, too. Imaging algorithms can now map tumors in three dimensions, showing exactly where blood vessels or immune cells cluster, guiding doctors to where treatments will work best. Combined with genomic data, these models create a digital twin of each tumor - allowing therapies to be tailored with unprecedented precision.

The problem of sleeper cells: Even when treatment seems successful, some cancer cells simply go quiet. They enter a state known as dormancy, hiding in tissues for years before suddenly waking up and causing relapse. These sleeper cells are nearly invisible to scans and often resistant to chemotherapy, which targets dividing cells.

To address this, scientists are studying the survival programs that let dormant cells persist. Some rely on a self-recycling process called autophagy, which helps them endure stress and scarcity. Drugs that block these pathways are now being tested, as are “wake-and-kill” approaches that gently coax dormant cells out of hiding before striking. Liquid biopsies, ultra-sensitive blood tests that detect tiny fragments of tumor DNA, are also helping doctors identify when dormant cells stir back to life, so intervention can start before relapse takes hold.

Making cell therapy work in solid tumors: One of the biggest revolutions in recent memory was CAR-T therapy, in which a patient’s own immune cells are engineered to hunt and destroy cancer. For blood cancers, it’s been transformative - in some cases, effectively curative. But for solid tumors, the results have been mixed. The reasons are clear: solid tumors are harder to reach, they vary more between cells, and their microenvironments suppress immune activity.

The new generation of CAR-T therapies aims to change that. Some are multi-targeted, recognizing several tumor markers at once to stop cancer from slipping through. Others are “armored” with genes that help them survive in hostile environments or release their own immune-activating molecules once inside. Still others use logic-gated circuits, so they attack only when specific combinations of signals appear - reducing the risk of harming healthy cells.

At the same time, companies are experimenting with in vivo CAR-T manufacturing, in which the reprogramming happens directly inside the body. If this succeeds, it could make these powerful treatments cheaper, faster, and available to far more people.

Finding and tracking cancer earlier than ever: Early detection remains one of the best routes to saving lives, but the next leap lies in making it universal and ultra-sensitive. Liquid biopsy technology can already detect traces of cancer DNA in the bloodstream, but new versions combine multiple layers of data - DNA, RNA, proteins, and even tiny particles called exosomes - to distinguish true cancer signals from noise.

This multi-omics approach, powered by AI pattern recognition, is turning detection into prediction. Algorithms can now learn from millions of patient samples, spotting subtle molecular fingerprints that hint at the very first stages of disease - long before a tumor forms.

Meanwhile, doctors are using minimal residual disease (MRD) testing to monitor patients after treatment, detecting whether any cancer cells are left and tailoring follow-up therapy accordingly. This kind of real-time, personalized monitoring could eventually replace routine scans with a single blood test that says whether cancer is gone, or trying to come back.

Expanding precision radiation from hospitals to everyone: Radiopharmaceuticals, radioactive medicines that travel through the bloodstream and attach directly to cancer cells, are one of the most promising frontiers. They’ve already shown survival benefits in prostate and neuroendocrine cancers, and now researchers are testing them in breast, lung, and gastrointestinal cancers. The biggest challenge is scale: producing the rare isotopes they rely on, ensuring safe delivery, and customizing doses to each patient.

To solve this, countries and companies are building new isotope production facilities, while scientists develop dosimetry algorithms that calculate optimal doses for individual patients. Some labs are experimenting with dual-function agents that combine radiation and drug payloads for an amplified effect. The goal is simple: make these life-extending treatments available beyond a few major centers, so they can reach patients everywhere.

Vaccines that train the immune system after cancer starts: The idea of a cancer vaccine once sounded far-fetched. But it’s now one of the most exciting areas in oncology. Unlike preventive vaccines such as HPV, these therapeutic vaccines are designed for people who already have cancer. They teach the immune system to recognize specific mutations, often unique to that patient’s tumor, and attack cells that display them.

Some of the most promising cancer-vaccine trials target mutations like KRAS, common in pancreatic and colorectal cancers. Others are fully personalized, built from a patient’s own tumor sequencing data. Early studies have shown strong immune responses and a lower risk of relapse - especially in advanced skin cancers, where personalized mRNA vaccines combined with immunotherapy have significantly improved outcomes. As production becomes faster and cheaper, these vaccines could soon become a routine part of post-surgery care - a personalized insurance policy against recurrence.

Rewriting the rules of clinical trials: Behind all these innovations lies another quiet revolution: the way we test new treatments. Traditional trials were slow, rigid, and linear - often taking a decade to move a single drug from concept to approval. Today, adaptive platform trials can test multiple drugs or combinations at once, dropping those that fail and expanding the ones that show promise.

AI and advanced genomics are turbocharging this shift. Algorithms analyze patient data in real time, identifying which mutations respond to which treatments. Trials can then adjust on the fly - enrolling more patients with matching tumor profiles or pivoting resources toward what works. This “learning-while-doing” model is already cutting years off development timelines, especially for targeted and immunotherapies.

Making sure progress reaches everyone: None of this progress will matter if it stays confined to wealthy countries or elite hospitals. The final challenge is equity - ensuring that early detection, cutting-edge drugs, and precision diagnostics reach people everywhere.

Tele-oncology and mobile screening programs are beginning to bridge this gap. Simplified diagnostics and at-home testing kits are helping bring care to rural and low-income regions. And organizations like the World Health Organization and Cancer Grand Challenges are working with governments to make essential treatments affordable and accessible.

Because a cure that only exists for some isn’t a cure at all.

The road ahead: The story of cancer has always been one of adaptation - both by the disease and by us. For every new defense cancer builds, science responds with a smarter strategy. Today, artificial intelligence, genomics, and bioengineering are allowing us to see and predict cancer in ways that once seemed impossible.

A universal cure may still be out of reach, but progress is redefining what it means to live with and beyond cancer. Treatments are becoming more precise, recovery rates are climbing, and many cancers that were once fatal are now manageable for years. The battle continues, but the odds are shifting steadily in humanity’s favor.

Next Time

Now that you understand why curing cancer has proven so difficult, the breakthroughs that have changed the odds, and the innovations scientists are racing to perfect - that’s only half the story.

In Part Two, we’ll shift the lens from science to business and look at the companies leading the charge - from pharmaceutical giants refining blockbuster drugs to AI labs, diagnostic innovators, and radiopharmaceutical startups quietly reshaping the field.

Not a subscriber and want Part Two and future deep dives delivered straight to your inbox? Join for free here.

Your Thoughts

This is just the second installment of our new deep-dive series, and I’d love to hear what you think.

Did this piece strike the right balance between depth and clarity? Was there anything you’d like to see explained differently, or topics you’d like explored next time?

Just hit reply - I read every message personally, and your feedback directly shapes how these deep dives evolve.

Share It Forward

If you found this deep dive useful, if it gave you a clearer picture of where cancer research is heading or a little more hope about the future, please share it with one person who’d appreciate it too.

That single act helps us reach more curious, optimistic readers and keeps this project growing.

See you soon,
Max

P.S. If a friend forwarded this, you can join free here to get Part Two and future deep dives straight to your inbox.